Ventripoint Diagnostics Announces Corporate Update and Shareholder Call
Toronto, Canada — February 19, 2026 — Leads & Copy — Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF), an AI-powered cardiac diagnostic solutions provider, has announced a corporate update and a shareholder videoconference call.
The company is focused on expanding the commercialization of VMS+™, strengthening clinical adoption, and positioning itself for revenue growth.
Since the last shareholder call, Ventripoint has progressed in regulatory execution, commercialization planning, clinical engagement, and operational readiness. Achievements include:
Commercial and Market Development:
- Refining the U.S. go-to-market approach to reduce sales friction and accelerate adoption.
- Engaging with prospective customers through virtual demonstrations.
- Aligning with distributors and partners in Europe and the United Kingdom to advance opportunities.
Partnerships and Strategic Initiatives:
- Continuing work with ASCEND Cardiovascular toward integration discussions and commercial alignment.
- Collaborating with the Ollie Hinkle Heart Foundation, supporting U.S. system placement opportunities.
- Collaborating with Lishman Global to support manufacturing and regulatory preparation in China for market entry.
- Evaluating potential distribution and strategic opportunities in Asia, including discussions with a family office group.
- Developing a strategy to expand VMS+™ into valvular and structural heart applications.
Technology, Product, and Regulatory:
- Executing commercialization activities for VMS+™ v4.0, including customer upgrade readiness and clinical workflow integration planning.
- Expanding internal focus on training, installation, and customer support systems, including developing scalable training materials and videos.
- Strengthening internal processes supporting quality and manufacturing readiness.
- Improving connectivity and integration workflows to support adoption into routine clinical practice.
Corporate Development and Team Expansion:
- Engaging with experienced commercial professionals for expanded roles upon financing completion.
- Engaging with governance-level candidates to strengthen board and advisory capacity in commercialization and capital markets.
Capital Markets and Financing:
- Advancing financing initiatives to secure growth capital while managing dilution.
- Engaging with capital markets advisors and investor awareness partners to broaden visibility.
The company will host a shareholder update call on Thursday, February 26, 2026, at 1pm EST. Details are available in the release. Meeting ID: 838 0964 8859 Passcode: 893160
Ventripoint is advancing its commercialization strategy and building the operational foundation for adoption and growth.
Sincerely,
Hugh MacNaught
President & CEO
Ventripoint is a leader in applying AI to echocardiography. The company’s VMS products are powered by Knowledge Based Reconstruction technology, providing accurate cardiac measurements equivalent to MRI. VMS+ is versatile and compatible with ultrasound systems and is supported by regulatory market approvals in the U.S., Europe, and Canada.
Source: Ventripoint Diagnostics Ltd.
Share this story:
